Relugolix for treating hormone-sensitive prostate cancer (TA995)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 August 2024
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (TA994)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2024
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases ID6512Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC